Text Size

Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

This study has been completed.
Sponsor:
Information provided by:
Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT00286351
First received: February 1, 2006
Last updated: April 20, 2007
Last verified: April 2007
History of Changes
  Purpose

Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome


Condition Intervention Phase
Endometriosis
 Drug: Combined treatment with Arimidex and Zoladex before IVF
 Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Resource links provided by NLM:

MedlinePlus related topics: Endometriosis
U.S. FDA Resources

Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • size of endometriomas after 2½ month of combined downregulation

Estimated Enrollment: 20
Study Start Date: January 2005
  Eligibility

Ages Eligible for Study:   20 Years to 40 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles
  • Couples with indication and wish for IVF/ICSI
  • Age of women: 20-40 years
  • Regular menstrual cycle within normal range (21-35 days)
  • Body Mass Index (BMI): 18-30 kg/m2

Exclusion Criteria:

  • History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease
  • Treatment of endometriosis with GnRH agonist during the last 3 month
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00286351

Locations
Denmark
The Fertility Clinic, Copenhagen University Hospital, Rigshospitalet
Copenhagen, Copenhagen East, Denmark, 2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Kristine Lossl, medical doctor The Fertility Clinic, Copenhagen University Hospital Rigshospitalet
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00286351     History of Changes
Other Study ID Numbers: endo 220604
Study First Received: February 1, 2006
Last Updated: April 20, 2007
Health Authority: Denmark: National Board of Health

Additional relevant MeSH terms:
Endometriosis
Genital Diseases, Female
Goserelin
Anastrozole
Antineoplastic Agents, Hormonal
Antineoplastic Agents
 Therapeutic Uses
Pharmacologic Actions
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 18, 2013